{
  "guideline": {
    "id": "PA166104938",
    "name": "Annotation of DPWG Guideline for acenocoumarol and VKORC1",
    "source": "DPWG",
    "version": 35,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104938",
    "relatedChemicals": [
      {
        "id": "PA452632",
        "name": "acenocoumarol",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA133787052",
        "name": "vitamin K epoxide reductase complex subunit 1",
        "symbol": "VKORC1"
      }
    ],
    "recommendation": true,
    "guidelineGenes": [
      {
        "alleles": [
          {
            "id": 1451903700,
            "_label": "rs9923231 reference (C)",
            "function": {
              "term": "Normal coumarin sensitivity",
              "termId": "alleleFunction:1451694741"
            }
          },
          {
            "id": 1451903701,
            "_label": "rs9923231 variant (T)",
            "function": {
              "term": "Higher coumarin sensitivity",
              "termId": "alleleFunction:1451694740"
            }
          }
        ],
        "gene": {
          "chr": {
            "id": "PA515",
            "name": "chr16",
            "symbol": null
          },
          "strand": "minus",
          "id": "PA133787052",
          "name": "vitamin K epoxide reductase complex subunit 1",
          "symbol": "VKORC1"
        }
      }
    ]
  },
  "annotationGroups": [
    {
      "id": "PA166264821",
      "name": "-1639 AA",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "VKORC1:Higher coumarin sensitivity/Higher coumarin sensitivity"
      ],
      "metabolizerStatus": null,
      "recommendation": {
        "id": 1451903822,
        "html": "<p>Monitoring by the ANTICOAGULATION CLINIC (National INR Monitoring Service):</p>\n<ul>\n<li>recommend to use 50% of the standard initial dose</li>\n</ul>\n<p>OTHERWISE:</p>\n<ul>\n<li>recommend to use 50% of the standard initial dose</li>\n<li>recommend more frequent monitoring of the INR</li>\n</ul>\n"
      },
      "implications": {
        "id": 1451903820,
        "html": "<p>An INR â‰¥ 6, resulting in an increased risk of bleeding, occurs in 8-12% of these patients during the first weeks of treatment with standard regulation by the Anticoagulation Clinic. The genetic variation increases the sensitivity to acenocoumarol.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166264822",
      "name": "-1639 AG",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "No",
        "termId": "rxChange:1448602495"
      },
      "genePhenotypes": [
        "VKORC1:Higher coumarin sensitivity/Normal coumarin sensitivity"
      ],
      "metabolizerStatus": null,
      "recommendation": {
        "id": 1451903783,
        "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
      },
      "implications": {
        "id": 1451903781,
        "html": "<p>The genetic variation results in a reduction of the required dose, but with the current practice of initiating or reviewing treatment this results in little or no increased risk of\nbleeding or excessive anticoagulation.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166264823",
      "name": "-1639 GG",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "No",
        "termId": "rxChange:1448602495"
      },
      "genePhenotypes": [
        "VKORC1:Normal coumarin sensitivity/Normal coumarin sensitivity"
      ],
      "metabolizerStatus": null,
      "recommendation": {
        "id": 1451903802,
        "html": "<p>The guideline does not provide a recommendation for acenocoumarol in patients with the VKORC1 rs9923231 CC genotype (-1639 GG genotype).</p>\n"
      },
      "implications": {
        "id": 1451903800,
        "html": "<p>The guideline does not provide a description of the impact of the -1639 GG genotype on acenocoumarol.</p>\n"
      },
      "activityScore": null
    }
  ],
  "citations": [
    {
      "pmid": "21412232",
      "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "authors": [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2011
    }
  ],
  "version": "2022-10-13-18-52"
}